Learn about key symptoms of renal cell carcinoma such as hematuria (blood in the urine), flank pain, and a palpable mass, as well as less common symptoms like…
Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses side effects associated with the novel…
David A. Braun, MD, PhD, physician at Dana-Farber Cancer Institute and instructor of medicine at Harvard Medical School, explains that while PD-1 blockade and immune therapies have been…
Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, reports recent findings from a study using pembrolizumab and lenvatinib as a second-line treatment for clear cell…
Scott Tykodi, MD, PhD, physician at Seattle Cancer Care Alliance, associate professor in the Division of Medical Oncology at University of Washington Medicine, and associate professor in the…
Toni K. Choueiri, MD, director of the Lank Center for Genitourinary Oncology, director of the Kidney Cancer Center, senior physician at Dana-Farber Cancer Institute, and Jerome and Nancy…
Yousef Zakharia, MD, clinical associate professor of internal medicine at the University of Iowa Holden Comprehensive Cancer Center, discusses completing a recent phase 1 trial studying seleno-L-methionine (SLM)…
Elizabeth R. Plimack, MD, MS, chief of the Division of Genitourinary Medical Oncology, director of Genitourinary Clinical Research, and professor in the Department of Hematology/Oncology at Fox Chase…
Bradley McGregor, MD, clinical director at Lank Center for Genitourinary Oncology, senior physician at Dana-Farber Cancer Institute, and instructor of medicine at Harvard Medical School, discusses a new…
Daniel George, MD, questions whether debulking nephrectomy is still necessary in the age of targeted therapies. In a one-sided non-inferiority study, sunitinib alone was compared to nephrectomy. The…